ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer
Tatiana Galicia-Carmona, Eder Arango-Bravo, Juan Alberto Serrano-Olvera, Celia Flores-de la Torre, Iván Cruz-Esquivel, Ricardo Villalobos-Valencia, Andrés Morán-Mendoza, Denisse Castro-Eguiluz, Lucely Cetina
Abstract
-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.
Topics & Concepts
Listeriolysin OCTL*AntigenCervical cancerCytotoxic T cellMedicineImmunotherapyImmunologyAdjuvantCancerCancer researchCancer immunotherapyVirologyCancer vaccineHPV infectionImmune systemBiologyCD8Listeria monocytogenesInternal medicineIn vitroListeriaBiochemistryGeneticsBacteriaCancer Research and TreatmentsImmunotherapy and Immune ResponsesVirus-based gene therapy research